Recombinantly engineered, lipase / esterase-deficient mammalian cell lines
Genetically engineered mammalian cell lines with reduced HCP activity and specific chromatography methods address the challenge of polysorbate degradation, improving the stability and shelf life of bioproduct formulations by minimizing HCP contamination and simplifying purification processes.
Patent Information
- Application Number
- JP2024152049
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-10-15
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-10-14
AI Technical Summary
Existing biopharmaceutical production methods face challenges in separating host cell proteins (HCPs) from recombinant proteins, particularly due to the degradation of polysorbates by lipases/esterases, which affects the stability and shelf life of bioproduct formulations, posing safety risks and complicating purification processes.
Genetically engineered mammalian cell lines with reduced expression and activity of endogenous palmitoyl protein thioesterase (PPT1) and other HCPs like lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase A2, and phospholipase D are developed, combined with specific chromatography methods to purify recombinant proteins and stabilize polysorbate-containing formulations.
The engineered cell lines significantly reduce polysorbate degradation, enhancing the stability and shelf life of bioproduct formulations, thereby simplifying purification processes and ensuring safer, more effective recombinant protein-based drugs.
Smart Images

Figure 2024163244000004 
Figure 2024163244000005 
Figure 2024163244000006
Abstract
Description
[Technical field]
[0001] The present invention relates to engineered mammalian cell lines, methods of producing same, methods of producing recombinant proteins in said cell lines, and compositions comprising recombinant proteins produced in said cell lines. [Background technology]
[0002] Mammalian cells, such as Chinese Hamster Ovary (CHO) cells, are used extensively in the biopharmaceutical industry to produce recombinant proteins, including therapeutic proteins, peptides, and monoclonal antibodies (mAbs). In the manufacturing process of a bioproduct, it is necessary to remove or reduce the co-produced host cell proteins (HCPs) in order to produce safe and effective drug, diagnostic, and / or research reagent products containing the recombinant protein. A wide variety of purification techniques have been utilized to purify recombinant proteins in bioproduct manufacturing. However, HCPs can be difficult to separate from recombinant proteins produced in mammalian cells. Thus, HCPs can present significant challenges in the production of recombinant proteins, especially in the manufacturing of therapeutic bioproducts. Methods for reducing either the expression or activity of problematic HCPs in mammalian cells used for the manufacturing of bioproducts can greatly reduce the complexity of the purification process required for the production of recombinant proteins. The use of cell lines with reduced HCPs often results in more stable, safer, and / or more effective recombinant protein-based drugs, diagnostics, and / or diagnostic research reagents.
[0003] In the production of recombinant protein products, polysorbates are often used in biomedical formulations to improve protein stability during manufacture, shipping, and storage. Polysorbates can improve the stability of bioproducts, particularly by reducing aggregation and particle formation due to interfacial stress, as well as surface adhesion of active ingredients. However, polysorbates (which are fatty acid esters of polyoxyethylene sorbitan) in the presence of certain lipases / esterases can undergo degradation to release long-chain fatty acids. This can occur, for example, by ester hydrolysis. Polysorbate degradation can reduce the effectiveness of the surfactant in protecting the active pharmaceutical ingredient (API), cause turbidity and particle formation of the formulation over time, making the product non-compliant and limiting its shelf life, and polysorbate degradation products may represent a risk to patient safety risks. The shelf life of recombinantly produced bioproduct formulations containing polysorbate detergents can be increased by reducing or eliminating the cellular lipases / esterases responsible for the enzymatic degradation of polysorbate detergents. Increased shelf life is important for efficient supply of recombinant products that reduces waste and enables distribution networks.
[0004] International Patent Publications WO2017 / 053482, WO2016 / 138467, WO2018 / 039499, and WO2015 / 095568 describe methods for reducing the expression of problematic HCPs in mammalian cells, including various lipases / esterases. However, it is often unclear which lipase / esterase causes the specific problem associated with polysorbate degradation. Thus, there remains a critical need for engineered lipase / esterase-deficient mammalian cells that more effectively address the problem of residual mammalian cell lipase / esterase activity in recombinant protein production methods and polysorbate-containing bioproduct formulations. The present invention provides, inter alia, engineered host cells that enable the production of bioproducts with significantly less polysorbate-degrading host cell protein contaminants and significantly improve stability in polysorbate-containing bioproduct formulations. Summary of the Invention
[0005] In one aspect, a mammalian cell is provided having reduced expression and / or activity of at least one endogenous palmitoyl protein thioesterase (PPT) and at least one HCP selected from the group consisting of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase A2, and phospholipase D.
[0006] In another aspect, there is provided a method for reducing polysorbate degradation in a protein formulation, comprising: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying a host cell to increase the expression of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 ) reducing or eliminating expression of (c) transfecting the cell with a polynucleotide encoding a biological product; (d) extracting a protein fraction containing the protein of interest from the host cells; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) collecting the protein of interest from the medium; (g) mixing the bioproduct with a fatty acid ester; (h) optionally adding a buffer; (i) optionally adding one or more pharma- ceutically acceptable carriers, diluents, or excipients.
[0007] In another aspect, there is provided a method for reducing aggregation or particle formation in a protein formulation, comprising the steps of: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying a host cell to increase the expression of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 ) reducing or eliminating expression of (c) transfecting the cell with a polynucleotide encoding a biological product of interest; (d) extracting a protein fraction containing the protein of interest from the host cells; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) collecting the protein of interest from the medium; (g) mixing the protein of interest with a fatty acid ester; (h) optionally adding a buffer; (i) optionally adding one or more pharma- ceutically acceptable carriers, diluents, or excipients.
[0008] In another aspect, a method for producing a stable formulated biological product is provided, comprising: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying a host cell to increase the expression of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 ) reducing or eliminating expression of (c) transfecting the cell with a polynucleotide encoding a biological product; (d) extracting a protein fraction comprising the bioproduct from the host cells; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) harvesting the biological product from the medium; (g) mixing the bioproduct with a fatty acid ester; (h) optionally adding a buffer; (i) optionally adding one or more pharma- ceutically acceptable carriers, diluents, or excipients. [Brief description of the drawings]
[0009] [Figure 1] 1 is a graph showing the temperature-dependent decomposition of PS80 monooleate ester over time in the presence of PPT1, which shows that PPT1 degrades PS80 in a temperature-dependent manner over time. [Diagram 2] Graph showing degradation of PS80 monooleate ester over time in formulated mAb samples spiked separately with (A) LAL-1 ppm, (C) LPL-1 ppm, (D) PPT1-1 ppm, and (E) LPLA2-0.1 ppm, showing that the PS80 monooleate ester present in the formulation degrades to a greater extent over time in the presence of these proteins than the formulated mAb control. [Diagram 3] Graph showing the degradation of PS80 monooleate ester over time in a control sample (A) and in the presence of 0.25 UN / mL PLD4 (B), 2.5 UN / mL PLD4 (D), 0.25 UN / mL PLD7 (C), and 2.5 UN / mL PLD7 (E). The data qualitatively demonstrate the ability of members of the PLD family to degrade PS80 over time. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] As used herein, the term "antibody" refers to an immunoglobulin molecule that binds to an antigen. Antibody embodiments include monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, bispecific or multispecific antibodies, or conjugated antibodies. The antibody may be of any class (e.g., IgG, IgE, IgM, IgD, IgA) and any subclass (e.g., IgG1, IgG2, IgG3, IgG4).
[0011] An exemplary antibody of the present disclosure is an immunoglobulin G (IgG) type antibody composed of four polypeptide chains: two heavy chains (HC) and two light chains (LC) cross-linked via interchain disulfide bonds. The amino terminal portion of each of the four polypeptide chains contains a variable region of about 100-125 or more amino acids that is primarily responsible for antigen recognition. The carboxy terminal portion of each of the four polypeptide chains contains a constant region that is primarily responsible for effector function. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region. Each light chain is composed of a light chain variable region (VL) and a light chain constant region. The IgG isotype can be further divided into subclasses (e.g., IgG1, IgG2, IgG3, and IgG4).
[0012] The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). The CDRs are exposed on the surface of the protein and are the regions of the antibody that are important for antigen-binding specificity. Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Herein, the three CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3" and the three CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3". The CDRs contain most of the residues that form specific interactions with the antigen.The assignment of amino acid residues to CDRs has been reported by Kabat (Kabat et al., "Sequences of Proteins of Immunological Interest", National Institutes of Health, Bethesda, Md. (1991)), Chothia (Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins", Journal of Molecular Biology, 196, 901-917 (1987), Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), North (North et al., "A New Clustering of Antibody CDR Loop Conformations", Journal of Molecular Biology, 406, 228-256 (2011)), or IMGT (the international ImMunoGeneTics database available at www.imgt.org; see Lefranc et al., Nucleic Acids Res. 1999; 27:209-212).
[0013] Embodiments of the present disclosure also include antibody fragments, including but not limited to, Fc fragments, or antigen-binding fragments, which contain at least a portion of an antibody that retains the ability to specifically interact with an antigen or an epitope of an antigen, such as a Fab, Fab', F(ab')2, Fv fragment, scFv antibody fragment, scFab, disulfide-linked Fv (sdFv), Fd fragment, as used herein.
[0014] As used herein, the term "fatty acid hydrolase" or "FAH" is intended to refer to any hydrolase that cleaves at a carbonyl group to produce a carboxylic acid product, which contains an R group that is lipophilic or otherwise hydrophobic. In some cases, the carboxylic acid product is a fatty acid.
[0015] The term "polysorbate" refers to a non-ionic surfactant that is a fatty acid ester of polyethoxylated sorbitan. Examples of polysorbates used in biomedical formulations include, but are not limited to, polysorbate 80 (PS80), polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60), polysorbate 65 (PS65), or combinations thereof. The concentration of polysorbate in the pharmaceutical composition of the present invention may be about 0.01% to about 1% by weight, preferably about 0.01% to about 0.10% by weight, more preferably about 0.01% to about 0.05% by weight, and even more preferably about 0.02% to about 0.05% by weight in the composition of the present invention.
[0016] As used herein, the term "lipase / esterase" is intended to mean a group of mammalian cell enzymes consisting of both "esterases" and "lipases." "Esterases" are a subgenus of fatty acid hydrolases that cleave fatty acid esters into fatty acids and alcohols. "Lipases" are a subgenus of esterases that cleave lipids (fats, waxes, sterols, glycerides, and phospholipids). "Phospholipases" are a subgenus of lipases that cleave phospholipids.
[0017] Palmitoyl protein thioesterase 1 (PPT1) is a member of the palmitoyl protein thioesterase family and is a lysosomal enzyme involved in the catabolism of lipid-modified proteins during lysosomal degradation, cleaving thioesters formed from fatty acid palmitate from cysteine residues in proteins. In one embodiment, Chinese hamster PPT1 comprises the amino acid sequence of SEQ ID NO: 1. In one embodiment, PPT1 is modified by ZFNs with a binding / cleavage region nucleic acid sequence of SEQ ID NO: 8. Lysosomal acid lipase (LAL), also known as lysosomal lipase, lipase A, lysosomal acid and cholesterol esterase, is an intracellular lipase that functions in lysosomes. LAL catalyzes the cleavage of cholesteryl ester bonds. In one embodiment, Chinese hamster LAL comprises the amino acid sequence of SEQ ID NO: 2. In one embodiment, LAL is modified by ZFNs with a binding / cleavage region nucleic acid sequence of SEQ ID NO: 7.
[0018] Lipoprotein lipase isoform X2 (herein referred to as LPL) is a glycosylated homodimer secreted by parenchymal cells and associated with endothelial cells in the capillary lumen. In one embodiment, Chinese hamster LPL comprises the amino acid sequence of SEQ ID NO:3. In one embodiment, LPL is modified by ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO:6.
[0019] Group XV lysosomal phospholipase A2 isoform X1 (referred to herein as LPLA2) is a member of a family of major lipid metabolism enzymes that cleave fatty acids from the sn-2 position of membrane phospholipids. In one embodiment, Chinese hamster LPLA2 comprises the amino acid sequence of SEQ ID NO: 4. In one embodiment, LPLA2 is modified by ZFNs with the binding / cleavage region nucleic acid sequence of SEQ ID NO: 5.
[0020] PLD3 is a member of the phospholipase D (PLD) lipid signaling enzyme superfamily. PLD family members are known to hydrolyze phosphatidylcholine to generate phosphatidic acid and choline. PLD3 is an N-glycosylated type II transmembrane protein and carries an HKD motif that has been shown to confer phosphodiester hydrolysis activity to other PLD family members (e.g., PLD1 and PLD2). In one embodiment, Chinese hamster PLD3 comprises the amino acid sequence of SEQ ID NO:9. In one embodiment, PLD3 is modified by ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO:10.
[0021] The terms "mammalian cell" and "host cell" are used interchangeably herein and refer to mammalian cells commonly used in the production of bioproducts using recombinant DNA technology. For example, Chinese Hamster Ovary (CHO) cells, human embryonic kidney 293 (HEK293), and mouse myeloma cells, including NS0 and Sp2 / 0 cells, are mammalian cells commonly used for protein expression. Preferably, the mammalian cell is CHO, including but not limited to CHO-K1, CHO pro-3, DUKX-X11, DG44, CHOK1SV, or CHOK1SV GS-KO. The parent cell line may also be modified by the insertion, knockout, or knockdown of genes that affect important quality characteristics or other post-translational modifications of the recombinant bioproduct polypeptide, or the expression of genes encoding the recombinant bioproduct. In an embodiment, the host cell is a Chinese Hamster Ovary (CHO) cell. In one embodiment, the host cell is a CHO-K1 cell, a CHOK1SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHO-S, a CHO GS knockout cell (glutamine synthetase), a CHOK1SV FUT8 knockout cell, a CHOZN, or a CHO-derived cell. A CHO GS knockout cell (e.g., a GSKO cell) is, for example, a CHO-K1SV GS knockout cell (Lonza Biologics, Inc.). A CHO FUT8 knockout cell is, for example, Potelligent® CHOK1SV FUT8 knockout (Lonza Biologics, Inc.).In embodiments, the host cell is a HeLa, MDCK, Sf9, Sf21, Tn5, HT1080, NB324K, FLYRD18, HEK293, HEK293T, HT1080, H9, HepG2, MCF7, Jurkat, NIH3T3, PC12, PER.C6, BHK (baby hamster kidney), VERO, SP2 / 0, NS0, YB2 / 0, Y0, EB66, C127, L cell, COS (e.g., COS1 and COS7), QC1-3, CHOK1, CHOK1SV, Potelligent™ (CHOK1SV FUT8-KO), CHO GS knockout, Xceed™ (CHOK1SV GS-KO), CHOS, CHO DG44, CHO DXB11, or CHOZN cell, or any cell derived therefrom.
[0022] The term "parent cell line" as used herein refers to non-transgenic protein product expressing mammalian cells that are commonly used to engineer protein expression. In some embodiments of the present invention, the parent cell line is a CHO, HEK293, or NS0 cell line. Preferably, the parent cell line is a CHO cell line, including but not limited to GS-CHO (CHOK1SV or CHOK1SV GS-KO) cell line.
[0023] The term "product expressing cell line" refers to a "parent cell line" into which one or more genes encoding at least one bioproduct have been inserted and which is capable of expressing such protein or proteins. Preferably, the "product expressing cell line" expresses an antibody, or an antigen-binding fragment thereof.
[0024] The term "indel" refers to the insertion or deletion of a nucleic acid base in the genome of a cell.
[0025] As used herein, the term "bioproduct" refers to a recombinant protein-based product of interest derived from mammalian cells genetically engineered using recombinant DNA technology. For example, bioproducts may include antibodies, antigen-binding fragments thereof, vaccines, growth factors, cytokines, hormones, peptides, enzymes, fusion proteins. Preferably, bioproducts are useful for therapeutic, diagnostic, industrial, and / or research applications.
[0026] The term "inactivated gene" refers to a gene that has been altered such that 1) it does not express detectable levels of the protein originally encoded by the unaltered wild-type gene, and / or 2) the protein encoded by the altered gene is phenotypically non-functional compared to the protein originally encoded by the unaltered wild-type gene.
[0027] The term "disrupted gene" refers to a gene that has been altered such that 1) expression of the protein originally encoded by the unaltered wild-type gene is reduced, and / or 2) the activity of the protein encoded by the altered gene is reduced compared to the activity of the protein encoded by the unaltered wild-type gene.
[0028] The terms "protein" and "polypeptide" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses amino acid polymers that are modified naturally or by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. The definition also includes, for example, proteins that contain one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), and other modifications known in the art. Examples of proteins include, but are not limited to, antibodies, peptides, enzymes, receptors, hormones, regulators, antigens, binding agents, cytokines, Fc fusion proteins (e.g., the Fc domain of an IgG genetically linked to a peptide / protein of interest), immunoadhesin molecules, and the like.
[0029] In one aspect of the present invention, a mammalian cell is provided having reduced expression and / or activity of at least one endogenous palmitoyl protein thioesterase (PPT) and at least one HCP selected from the group consisting of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase A2, and phospholipase D. In another aspect of the present invention, the mammalian cell is further modified to express at least one bioproduct. The bioproduct may be, for example, 1) a polypeptide, 2) an antibody, or a fragment thereof, including but not limited to, an antigen-binding fragment thereof, or 3) a protein-protein fusion, including but not limited to, an Fc fusion protein.
[0030] In one aspect of the present invention, a mammalian cell is provided having reduced expression and / or activity of endogenous palmitoyl protein thioesterase 1 (PPT1) and at least one HCP selected from the group consisting of lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase A2 (LPLA2), and phospholipase D3 (PLD3).
[0031] In one aspect of the present invention, lysosomal acid lipase (LAL) protein, lipoprotein lipase (LPL) protein, phospholipase A2 (LPLA) protein, 2 ) protein, and palmitoyl protein thioesterase 1 (PPT1) protein, wherein the modification is in a coding sequence of a polynucleotide encoding the LAL protein, LPL protein, LPLA protein, and the palmitoyl protein thioesterase 1 (PPT2) protein, and the modification is in a coding sequence of a polynucleotide encoding the LAL protein, LPL protein, LPLA protein, and the palmitoyl protein thioesterase 1 (PPT3) protein, and the modification is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT4) protein, wherein the modification is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT1) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT2) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT3) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT4) protein is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT1) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT3) protein is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT4) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT4) protein is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT1) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT1) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT1) protein is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT2) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT3) protein is in a coding sequence of a polynucleotide encoding the palmitoyl protein thioesterase 1 (PPT3) protein, and the polynucleotide encoding the palmitoyl protein thioesterase 1 2 Proteins and mammalian cells that reduce the expression levels of the PPT1 protein are provided.
[0032] In another embodiment of the invention, the mammalian cell is further modified to express at least one bioproduct, which may be, for example, 1) a polypeptide, 2) an antibody or a fragment thereof, including but not limited to an antigen-binding fragment thereof, or 3) an Fc fusion protein.
[0033] In another aspect of the invention, a mammalian cell is provided in which the genes of the cell encoding endogenous PPT1 and at least one other polysorbate-degrading HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 have been modified, thereby reducing the expression and / or activity of endogenous PPT1 and other secreted HCPs. Preferably, endogenous PPT1 and LAL, LPL, LPLA2, and PLD3 are modified, thereby reducing the expression and / or activity of endogenous PPT1 and other secreted HCPs. 、and PLD3, the activity and / or expression of at least one HCP selected from the group consisting of PPT1, LAL, LPL, LPLA2, and PLD3 is substantially reduced or completely eliminated. In another aspect, a method is provided for producing a mammalian cell in which the genes encoding endogenous PPT1 and at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 are modified to reduce the expression and / or activity of those HCPs. Preferably, the activity and / or expression of endogenous PPT1 and at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 is substantially reduced or completely eliminated. In another aspect of the present invention, a method is provided for producing a recombinant protein in the mammalian cell embodiments described herein. The material produced from the mammalian cell embodiments described herein does not exhibit or significantly reduces hydrolytic polysorbate degradation, and the associated lipase activity is essentially not measurable (such as in a lipolytic activity assay).
[0034] In some embodiments, the bioproducts produced from the mammalian cells of the present invention provide a Protein A binding fraction with a substantially reduced polysorbate degradation activity compared to the polysorbate degradation activity of the same bioproducts produced in essentially similar cells without any of the modifications. In some embodiments, the reduction in intact polysorbate degradation resulting from the bioproducts produced in cell lines expressing the products of the present invention compared to the intact polysorbate degradation resulting from the same bioproducts produced in cell lines expressing the corresponding unmodified products is about 20% or more, 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, or about 80% or more. In some embodiments, the reduction in degradation of intact polysorbate resulting from a bioproduct produced in a cell line expressing a product of the invention compared to the degradation of intact polysorbate resulting from the same bioproduct produced in a cell line expressing the corresponding unmodified product is 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, or 80% or more.
[0035] In some embodiments, the reduction in degradation of intact polysorbate resulting from a bioproduct produced in a cell line expressing a product of the invention compared to the degradation of intact polysorbate resulting from the same bioproduct produced in a cell line expressing the corresponding unmodified product is between about 20% to about 80%, between about 30% to about 75%, between about 35% to about 70%, between about 40% to about 65%, or between about 45% to about 60%.
[0036] In some embodiments, the reduction in degradation of intact polysorbate resulting from a biological product produced in a cell line expressing a product of the invention compared to the degradation of intact polysorbate resulting from the same biological product produced in a cell line expressing the corresponding unmodified product is between 20% and 80%, between 30% and 75%, between 35% and 70%, between 40% and 65%, and between 45% and 60%.
[0037] In one aspect of the present invention, gene editing methods are utilized to target the gene encoding endogenous PPT1 and at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 to edit, disrupt, and / or inactivate them, for example, for modifying, inserting, or deleting genomic loci.In some embodiments, one or both alleles of endogenous host cell protein, PPT1, and at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 are knocked out from the genome of engineered host cell (e.g., CHO cell) described herein.For example, gene editing methods include, but are not limited to, the use of zinc finger nuclease (ZFN), clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), and meganuclease system.
[0038] In one aspect of the invention, a recombinantly engineered mammalian cell is provided that comprises a modification in a polynucleotide sequence encoding an LAL protein, an LPL protein, an LPLA2 protein, and an endogenous PPT1 protein. In another aspect of the invention, the modification reduces the expression level of the LAL protein, the LPL protein, the LPLA2 protein, and the PPT1 protein compared to the expression level of a cell lacking the modification, e.g., a wild-type mammalian cell.
[0039] In some embodiments, the target HCP gene is edited, disrupted, and / or inactivated by gene deletion. As used herein, "gene deletion" refers to removing at least a portion of a DNA sequence from or adjacent to a gene. In some embodiments, the sequence subjected to gene deletion comprises an exon sequence of the gene. In some embodiments, the sequence subjected to gene deletion comprises a promoter sequence of the gene. In some embodiments, the sequence subjected to gene deletion comprises a flanking sequence of the gene. In some embodiments, the sequence subjected to gene deletion comprises a sequence encoding a signal peptide of the targeted HCP. In some embodiments, a portion of the target HCP gene sequence is removed from the target HCP gene or from a region relatively close to the target HCP gene. In some embodiments, the entire target HCP gene sequence is removed from the chromosome. In some embodiments, the mammalian cell comprises a gene deletion adjacent to the target HCP gene. In some embodiments, the target HCP gene is edited, disrupted, and / or inactivated by gene deletion, where the deletion of at least one nucleotide or nucleotide base pair in the gene sequence results in a non-functional gene product. In some embodiments, the target HCP gene is edited, disrupted, and / or inactivated by gene deletion, where deletion of at least one nucleotide of the gene sequence results in a gene product that no longer has the function or activity of the original gene product, or is dysfunctional.
[0040] In some embodiments, the target HCP gene is edited, disrupted, and / or inactivated by gene addition or replacement. As used herein, "gene addition" or "gene replacement" refers to an alteration of the target HCP gene sequence, including the insertion or replacement of one or more nucleotides or nucleotide base pairs. In some embodiments, the intron sequence of the target HCP gene is altered. In some embodiments, the exon sequence of the target HCP gene is altered. In some embodiments, the promoter sequence of the target HCP gene is altered. In some embodiments, the flanking sequence of the target HCP gene is altered. In some embodiments, the sequence encoding the signal peptide of the target HCP is altered. In some embodiments, one nucleotide or nucleotide base pair is added to the target HCP gene sequence. In some embodiments, at least one contiguous nucleotide or nucleotide base pair is added to the target HCP gene sequence. In some embodiments, the target HCP gene is inactivated by gene addition or replacement, where the addition or replacement of at least one nucleotide or nucleotide base pair to the target HCP gene sequence results in a non-functional gene product. In some embodiments, the target HCP gene is inactivated by gene inactivation, where the incorporation or substitution of at least one nucleotide into the target HCP gene sequence results in a gene product that no longer has the function or activity of the original gene product, or is dysfunctional.
[0041] In general, CRISPR system includes a caspase protein such as Cas9 and an RNA sequence that includes a nucleotide sequence, called a guide sequence, that is complementary to a sequence of interest. Caspase and RNA sequence form a complex that identifies the DNA sequence of mammalian cells, and then the nuclease activity of caspase allows DNA strand cleavage. Caspase isotypes have single-stranded DNA or double-stranded DNA nuclease activity. The design of the guide RNA sequence and the number of guide RNA sequences used in CRISPR system allows removal of specific stretches of genes and / or addition of DNA sequences.
[0042] In some embodiments, the methods of the present invention comprise using at least one genome editing system selected from the group consisting of CRISPR, TALEN, ZFN, and meganuclease systems to edit, disrupt, and / or inactivate an endogenous PPT1-encoding gene and at least one HCP-encoding gene selected from the group consisting of LAL, LPL, LPLA2, and PLD3.
[0043] Generally, the TALEN system comprises one or more restriction nucleases and two or more protein complexes, allowing recognition of DNA sequences and subsequent cleavage of double-stranded DNA. The protein complexes of the TALEN system comprise a number of transcription activator-like effectors (TALEs), each of which recognizes a specific nucleotide, and a domain of the restriction nuclease. Generally, the TALEN system is designed such that two protein complexes, each of which comprises a domain of the TALE and the restriction nuclease, bind individually to the DNA sequence in a manner that allows the two domains of the restriction nuclease (one from each protein complex) to form an active nuclease and cleave a specific DNA sequence. The design of the number of protein complexes and sequences cleaved in the TALEN system allows the removal of specific stretches of genes and / or the addition of DNA sequences.
[0044] In some embodiments, the methods of the present invention include using a TALEN system to edit, disrupt, and / or inactivate an endogenous PPT1-encoding gene and at least one HCP-encoding gene selected from the group consisting of LAL, LPL, LPLA2, and PLD3.
[0045] In some embodiments, a method for producing mammalian cells having reduced levels of endogenous PPT1 and reduced levels of at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 comprises using a TALEN system to edit, disrupt, and / or inactivate endogenous PPT1 and at least one of the other target HCP genes (i.e., LAL, LPL, LPLA2, and PLD3).
[0046] Generally, ZFN systems contain one or more restriction nucleases and two or more protein complexes, allowing recognition of DNA sequences and subsequent cleavage of double-stranded DNA. The protein complexes of the ZFN system contain multiple zinc fingers, each of which recognizes a specific nucleotide codon, and a domain of the restriction nuclease. Generally, ZFN systems are designed such that two protein complexes, each of which contains a zinc finger and a domain of the restriction nuclease, bind individually to the DNA sequence in a manner that allows the two domains of the restriction nuclease (one from each protein complex) to form an active nuclease and cleave a specific DNA sequence. The design of the number of protein complexes and sequences cleaved by the ZFN system allows the removal of specific stretches of genes and / or the addition of DNA sequences.
[0047] In some embodiments, the methods of the invention comprise using a ZFN system to edit, disrupt, and / or inactivate an endogenous PPT1-encoding gene and at least one HCP-encoding gene selected from the group consisting of LAL, LPL, LPLA2, and PLD3.
[0048] In some embodiments, a method of producing mammalian cells having reduced levels of endogenous PPT1 and reduced levels of at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 comprises using a ZFN system to edit, disrupt, and / or inactivate endogenous PPT1 and at least one of the other target HCP genes (i.e., LAL, LPL, LPLA2, and PLD3).
[0049] Generally, a meganuclease system comprises one or more meganucleases, allowing the recognition of a DNA sequence and subsequent cleavage of double-stranded DNA.
[0050] In some embodiments, the methods of the present invention comprise using a meganuclease system to edit, disrupt, and / or inactivate a gene encoding endogenous PPT1 and a gene encoding at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3.
[0051] In some embodiments, a method for producing mammalian cells having reduced levels of endogenous PPT1 and reduced levels of at least one HCP selected from the group consisting of LAL, LPL, LPLA2, and PLD3 comprises using a meganuclease system to edit, disrupt, and / or inactivate endogenous PPT1 and at least one other target HCP gene (i.e., LAL, LPL, LPLA2, and PLD3).
[0052] The engineered host cells (e.g., CHO cells) described herein can include additional genomic modifications to alter the glycosylation pattern of antibodies produced in those cells. Altered glycosylation patterns, such as reduced fucosylation, have been shown to increase antibody-dependent cellular cytotoxicity (ADCC) activity of antibodies. For example, host cells that knock out both alleles of FUT8 (fucosyltransferase 8, or a-1,6-fucosyltransferase) can produce antibodies with enhanced ADCC activity (see U.S. Pat. No. 6,946,292). In some embodiments, the engineered host cells (e.g., CHO cells) described herein include genetic modifications to reduce fucosylation of antibodies. In some embodiments, the engineered host cells (e.g., CHO cells) described herein include an edited, disrupted, and / or inactivated FUT8 gene, for example, due to modification, insertion, or deletion of the FUT8 genomic locus. In some embodiments, one or both alleles of FUT8 are knocked out from the genome of the engineered host cells (e.g., CHO cells) described herein. Antibodies produced in such FUT8 knockout host cells may have increased ADCC activity. Other enzymes involved in glycosylation include GDP-mannose 4,6-dehydratase, GDP-keto-6-deoxymannose 3,5-epimerase 4,6-reductase, GDP-beta-L-fucose pyrophosphorylase, N-acetylglucosaminyltransferase III, and fucokinase. In some embodiments, the engineered host cells (e.g., CHO cells) described herein may contain inactivated genes encoding one or more of these enzymes. In one embodiment, Chinese hamster FUT8 comprises the amino acid sequence of SEQ ID NO:11.
[0053] The engineered host cells (e.g., CHO cells) described herein can also include additional genomic modifications that affect the stability of the recombinant proteins they express. For example, cathepsin D (CatD) has been identified as a CHO HCP involved in the degradation of Fc-fusion recombinant proteins (see Robert, F.; et al. "Degradation of an Fc-Fusion Recombinant Protein by Host Cell Proteases: Identification of a CHO Cathepsin D Protease." Biotechnology and Bioengineering 2009, 104(6), 1132-1141). In some embodiments, the engineered host cells (e.g., CHO cells) described herein include an edited, disrupted, and / or inactivated CatD gene, for example, due to modification, insertion, or deletion of the CatD genomic locus. In some embodiments, one or both alleles of CatD are knocked out from the genome of the engineered host cells (e.g., CHO cells) described herein. Recombinant proteins produced in such knockout host cells may be less susceptible to degradation during production. In one embodiment, Chinese hamster CatD comprises the amino acid sequence of SEQ ID NO: 12. In one embodiment, CatD is modified by ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO: 13.
[0054] The engineered host cells (e.g., CHO cells) described herein can also contain additional genomic modifications that affect the heterogeneity of the recombinant proteins they express. For example, carboxypeptidase D (CpD) can cleave C-terminal lysines from IgG1, IgG2, and IgG4 monoclonal antibody isotypes (see International Patent Application Publication WO2017 / 053482). This can result in charge variants and can complicate manufacturing control strategies. In some embodiments, the engineered host cells (e.g., CHO cells) described herein contain an edited, disrupted, and / or inactivated CpD gene, for example, due to modification, insertion, or deletion of the CpD genomic locus. In some embodiments, one or both alleles of CpD are knocked out from the genome of the engineered host cells (e.g., CHO cells) described herein. Recombinant proteins produced in such knockout host cells can have reduced charge variant heterogeneity. In one embodiment, Chinese hamster CpD comprises the amino acid sequence of SEQ ID NO: 14. In one embodiment, the CpD is modified by a ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO:15.
[0055] The engineered host cells (e.g., CHO cells) described herein can also include additional genomic modifications that affect downstream processes used in producing recombinant proteins. For example, phospholipase B-like 2 (PLBL2) and peroxiredoxin-1 (PRDX1) are HCPs identified as contaminants in recombinant proteins produced in CHO cells after protein capture chromatography (see WO2016 / 138467 and Doneanu, C.; et al. "Analysis of host-cell proteins in biotheraputic proteins by comprehensive online two-dimensional liquid chromatography / mass spectrometry." mAbs 2012,4(1),24-44). In some embodiments, the engineered host cells (e.g., CHO cells) described herein include a gene or genes encoding one or both of the proteins of the group consisting of PLBL2 and PRDX1 that have been edited, disrupted, and / or inactivated, for example, due to modification, insertion, or deletion of a genomic locus or loci. In some embodiments, one or both alleles of a gene or genes encoding one or both proteins of the group consisting of PLBL2 and PRDX1 are knocked out from the genome of an engineered host cell (e.g., CHO cell) described herein. The recombinant protein produced in such a knockout host cell may have reduced HCP contaminants compared to the wild type and may require fewer downstream purification steps. In one embodiment, Chinese hamster PLBL2 comprises the amino acid sequence of SEQ ID NO: 16. In one embodiment, PLBL2 is modified by ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO: 17. In one embodiment, Chinese hamster PRDX1 comprises the amino acid sequence of SEQ ID NO: 18. In one embodiment, PRDX1 is modified by ZFN with the binding / cleavage region nucleic acid sequence of SEQ ID NO: 19.
[0056] In some embodiments, a mammalian cell of the invention (eg, a CHO cell) encodes a recombinant protein that is tanezumab (see, eg, WO2004 / 058184).
[0057] In some embodiments, the mammalian cells of the invention (eg, CHO cells) encode a recombinant protein that is lebrikizumab (see, eg, WO2005 / 062967).
[0058] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is mirikizumab (see, e.g., WO2014 / 137962).
[0059] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is solanezumab (see, eg, WO2001 / 62801).
[0060] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is donanemab (see, e.g., WO2012 / 021469).
[0061] In some embodiments, a mammalian cell (e.g., a CHO cell) of the invention encodes a recombinant protein that is zagotenemab (see, e.g., WO2016 / 137811).
[0062] In some embodiments, a mammalian cell of the invention (eg, a CHO cell) encodes a recombinant protein that is ramucirumab (see, eg, WO2003 / 075840).
[0063] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is galcanezumab (see, e.g., WO2011 / 156324).
[0064] In some embodiments, a mammalian cell of the invention (eg, a CHO cell) encodes a recombinant protein that is ixekizumab (see, eg, WO2007 / 070750).
[0065] In some embodiments, the mammalian cells of the invention (e.g., CHO cells) encode a recombinant protein that is dulaglutide (see, e.g., WO2005 / 000892).
[0066] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is necitumumab (see, e.g., WO2005 / 090407).
[0067] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is olaratumab (see, e.g., WO2006 / 138729).
[0068] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is cetuximab.
[0069] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is an Angiopoietin 2 mAb (see, e.g., WO2015 / 179166).
[0070] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is an insulin-Fc fusion protein (see, e.g., WO2016 / 178905).
[0071] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a CD200R agonist antibody (see, e.g., WO2020 / 055943).
[0072] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is an epiregulin / transforming growth factor alpha (epiregulin / TGFα) mAb (see, e.g., WO2012 / 138510).
[0073] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is an angiopoietin-like 3 / 8 (ANGPTL 3 / 8) antibody (see, e.g., WO2020 / 131264).
[0074] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is a B and T lymphocyte attenuator (BTLA) antibody agonist (see, e.g., WO2018 / 213113).
[0075] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is a CXC chemokine receptor 1 / 2 (CXCR1 / 2) ligand antibody (see, e.g., WO2014 / 149733).
[0076] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a growth / differentiation factor 15 (GDF15) agonist (see, e.g., WO2019 / 195091).
[0077] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is an interleukin-33 (IL-33) antibody (see, e.g., WO2018 / 081075).
[0078] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) antibody (see, e.g., WO2019 / 067293).
[0079] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a programmed cell death-1 (PD-1) antibody agonist (see, e.g., WO2017 / 025016).
[0080] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is pyroglutamate-Abeta (pGlu-Abeta, also known as N3pG Abeta) mAb (see, e.g., WO2012 / 021469).
[0081] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a tumor necrosis factor alpha / interleukin 23 (TNFα / IL-23) bispecific antibody (see, e.g., WO2019 / 027780).
[0082] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is an anti-alpha-synuclein antibody (see, e.g., WO2020 / 123330).
[0083] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode recombinant proteins that are cluster of differentiation 226 (CD226) agonist antibodies (see, e.g., WO2020 / 023312).
[0084] In some embodiments, a mammalian cell of the invention (e.g., a CHO cell) encodes a recombinant protein that is a monocarboxylate transporter 1 (MCT1) antibody (see, e.g., WO2019 / 136300).
[0085] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention encode a recombinant protein that is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody.
[0086] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is an anti-Fc gamma receptor IIB (FcgRIIB or FcγRIIB) antibody.
[0087] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is an anti-interleukin-34 (IL-34) antibody.
[0088] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is an anti-cluster of differentiation 19 (CD19) antibody.
[0089] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is the triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
[0090] In some embodiments, the mammalian cells (eg, CHO cells) of the invention encode a recombinant protein that is a relaxin analog.
[0091] In some embodiments, the mammalian cells (e.g., CHO cells) of the invention are capable of inhibiting or inhibiting any of the following antibodies: tanezumab, lebrikizumab, mirikizumab, solanezumab, donanemab, zagotenemab, ramucirumab, galcanezumab, ixekizumab, dulaglutide, necitumumab, olaratumab, cetuximab, angiopoietin 2 mAb, insulin-Fc fusion protein, CD200R agonist antibody, epiregulin / TGFα mAb, ANGPTL 3 / 8 antibody, BTLA antibody agonist, CXCR1 / 2 ligand antibody, GDF15 agonist, IL-33 antibody, PACAP38 antibody, PD-1 agonist antibody, N3pG Abeta The antibody encodes a recombinant protein selected from the group consisting of pGlu-Abeta, also known as mAb, TNFα / IL-23 bispecific antibody, anti-α-synuclein antibody, CD226 agonist antibody, MCT1 antibody, SARS-CoV-2 neutralizing antibody, FcgRIIB antibody, IL-34 antibody, CD19 antibody, TREM2 antibody, and relaxin analogue.
[0092] Embodiments of the invention also include the use of polysorbates in combination with tanezumab, lebrikizumab, mirikizumab, solanezumab, donanemab, zagotenemab, ramucirumab, galcanezumab, ixekizumab, dulaglutide, necitumumab, olaratumab, cetuximab, angiopoietin 2 mAb, insulin-Fc fusion protein, CD200R agonist antibody, epiregulin / TGFα mAb, ANGPTL 3 / 8 antibody, BTLA antibody agonist, CXCR1 / 2 ligand antibody, GDF15 agonist, IL-33 antibody, PACAP38 antibody, PD-1 agonist antibody, N3pG Abeta and a bioproduct selected from the group consisting of pGlu-Abeta, also referred to as mAb, TNFα / IL-23 bispecific antibody, anti-α-synuclein antibody, CD226 agonist antibody, MCT1 antibody, SARS-CoV-2 neutralizing antibody, FcgRIIB antibody, IL-34 antibody, CD19 antibody, TREM2 antibody, and relaxin analog, wherein the bioproduct is produced by a recombinant mammalian cell of the invention. In various embodiments, the polysorbate is polysorbate 80 (PS80), polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60), polysorbate 65 (PS65), or a combination thereof. The concentration of polysorbate in the pharmaceutical composition of the present invention may be about 0.01% by weight / volume (w / v) to about 1% by weight / volume (w / v), preferably about 0.01% by weight / volume (w / v) to about 0.10% by weight / volume (w / v), more preferably about 0.01% by weight / volume (w / v) to about 0.05% by weight / volume (w / v), and even more preferably about 0.02% by weight / volume (w / v) to about 0.05% by weight / volume (w / v). In other embodiments, the pharmaceutical composition of the present invention further comprises one or more pharma- ceutically acceptable carriers, diluents, or excipients.Pharmaceutical compositions containing biological products produced using the cell lines of the present invention can be further formulated by methods well known in the art (e.g., Remington: The Science and Practice a / Pharmacy, 19th edition (1995), (A. Gennaro et al., Mack Publishing Co.).
[0093] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1: Graph showing temperature-dependent decomposition of PS80 monooleate ester over time in the presence of PPT1, showing that PPT1 degrades PS80 in a temperature-dependent manner over time. FIG. 2: Graph showing the degradation of PS80 monooleate ester over time in formulated mAb samples with (A) control and (B) LAL-1 ppm, (C) LPL-1 ppm, (D) PPT1-1 ppm, and (E) LPLA2-0.1 ppm added separately, showing that the PS80 monooleate ester present in the formulation degrades to a greater extent over time in the presence of these proteins than the formulated mAb control. Figure 3: Graph showing the degradation of PS80 monooleate ester over time in a control sample (A) and in the presence of 0.25 UN / mL PLD4 (B), 2.5 UN / mL PLD4 (D), 0.25 UN / mL PLD7 (C), and 2.5 UN / mL PLD7 (E). The data qualitatively demonstrate the ability of members of the PLD family to degrade PS80 over time.
[0094] Without limiting the scope of the invention, the following preparations and examples provide those of ordinary skill in the art with the means to make and use the methods and compositions described herein. EXAMPLES
[0095] Example 1 - Characterization of the polysorbate hydrolysis activity of PPT1 Polysorbate Degradation Analysis by Liquid Chromatography-Mass Spectrometry (LCMS) - General Procedure A LCMS analysis is performed on a Waters ACQUITY UPLC (I class) equipped with a Waters SYNAPT® G2-Si mass spectrometer, column: Agilent PLRP-S 2.1×50 mm, 1000 Å, 5 μm particle size, mobile phase: A-0.05% trifluoroacetic acid (TFA) in water, B-0.04% TFA in acetonitrile. Standard solutions are prepared with 2% PS80 and 10 mM citrate buffer to obtain 0.001, 0.002, 0.005, 0.01, 0.025, 0.05% PS80 solutions. A standard curve of the prepared PS80 solutions in 10 mM citrate buffer is obtained to quantify intact PS80 in the samples by LCMS extracted ion chromatogram for polysorbate monooleate. Using the standard curve, the relative percent (%) of PS80 intact as the monooleate ester for each sample is calculated relative to time=zero.
[0096] Example 1a - Degradation of Polysorbate 80 in the Presence of PPT1 Polysorbate 80 (PS80) and PPT1 samples are prepared as follows: 0.5 mL of 0.02 w / v% PS80 in 10 mM citrate buffer (pH 6) is mixed with 5.6 μL of a 0.3 mg / mL solution of PPT1 (prepared by recombinant expression) and the samples are maintained at 4, 15, 25, and 35 °C for the duration of the study. Samples (50 μL) of these solutions are taken at time intervals and mixed with 5 μL of 5% formic acid in water for LCMS analysis. The percentage of intact PS80 remaining as the monooleate ester is monitored over time by LCMS using general procedure A. These data are shown in Figure 1 and show that PPT1 degrades PS80 over time in a temperature-dependent manner.
[0097] Example 1b - Degradation of Polysorbate 80 in mAb Formulation Samples Spiked with LAL, LPL, PPT1, and LPLA2 Samples of formulated mAb (Antibody 1, 100 mg / mL in 20 mM sodium acetate buffer, pH 5.0, containing 0.03 w / v% PS80) are separately spiked with 1 ppm of LAL, LPL, and PPT1, and 0.1 ppm of LPLA2 (obtained from recombinant expression). Samples are incubated at 37° C. for the duration of the study. Each sample is diluted 1:2 with 20 mM sodium acetate buffer and then analyzed by LCMS using general procedure A. The percentage of intact PS80 remaining as the monooleate ester over time is shown in Table 1 and FIG. 2. [Table 1]
[0098] These data indicate that the PS80 monooleate ester present in the formulation degrades to a greater extent over time in the presence of these proteins than the formulated mAb control.
[0099] The combined data in this example demonstrate the ability of these proteins (LAL, LPL, PPT1, and LPLA2) to degrade PS80 in solution over time.
[0100] Example 2 - Identification of PPT1 in Fc fusion protein formulations Two separate culture batches of Fc fusion protein (Fc fusion protein 1) are subjected to Protein A chromatography. An aliquot of the main stream of Protein A (25 μL) is mixed with 1 M Tris-HCl buffer, pH 8 (5 μL), Barnstead water (172 μL), protein standard mixture (0.8 μL), and 2.5 mg / mL bovine r-trypsin (2 μL). The sample is incubated at 37° C. for 16 hours. The sample is mixed with 2 μL of a 50 mg / mL dithiothreitol (DTT) solution and then heated at 90° C. for 10 minutes. The sample is centrifuged at 10,000 g for 2 minutes and the supernatant is transferred to a vial. The sample is then eluted in a 100 mL PBS. 2The mixture is acidified with 5% TFA in 0 (5 μL) and analyzed by LCMS. LCMS analysis is performed on a Waters ACQUITY UPLC equipped with a ThermoFisher Q Exactive™ Plus mass spectrometer, column: Waters UPLC CSH C18, 2.1×50 mm, 1.7 μm particle size, mobile phase: A-0.10% formic acid (FA) in water, B-0.10% FA in acetonitrile, with the column immersed in ice water. In this experiment, PPT1 is identified in a sample of Fc fusion protein 1 after Protein A purification by untargeted proteomics (DDA) approach at 0.5±0.1 ppm (n=2).
[0101] Example 3 - Generation of recombinantly engineered LPLA2, LAL, LPL, and PPT1 knockout CHO cell lines Unless otherwise stated, the cell culture medium used refers to serum-free cell culture medium supplemented with 8 mM glutamine.Furthermore, unless otherwise stated, the mammalian cells used are glutamine synthase-deficient CHO (GS-CHO) cell lines.
[0102] Engineering of the cell lines is accomplished through the use of custom zinc finger nuclease (ZFN) reagents constructed by Sigma Aldrich that are designed to be specific for each target HCP gene (CompoZr® Custom Zinc Finger Nucleases, Catalog No. CSTZFN, Sigma Aldrich, St. Louis, MO). The ZFN binding / cleavage region nucleic acid sequences for LPLA2, LPL, LAL, and PPT1 are shown in Table 2. [Table 2]
[0103] Preparation of cells for gene disruption - General procedure B The vial containing the cells is thawed in a 36°C water bath until only ice flakes remain. The cells are seeded in cell culture medium in shake flask cultures. Cultures of the parent cell line are subcultured in cell culture medium and maintained and passaged on a 3 day / 4 day schedule. Cell cultures are seeded as above at 0.2 x 10 cells in 30 mL of the appropriate maintenance medium. 6 Seed at a seeding density of 100 vc / mL. On the day of transfection, count the cells and collect an appropriate volume of cells.
[0104] ZFN transfection and bulk culture harvest - General procedure C ZFN transfection is performed using Nucleofector™ technology and the associated cGMP Nucleofector™ Kit V (catalog no. VGA-1003, Lonza, Basel, Switzerland). Briefly, a single Nucleofection reagent (2–4.5 × 10 6 Sufficient cells for 100 µL of Nucleofector™ solution V (vc) are harvested by centrifugation. After complete removal of the supernatant, the cell pellet is suspended in 100 µL of Nucleofector™ solution V, supplemented according to the manufacturer's protocol. The suspended cells are gently mixed by trituration and transferred to a vial containing an aliquot of ZFN mRNA [part of a custom ZFN kit produced by Sigma Aldrich (St. Louis, MO)]. The cell / mRNA mixture is then transferred to a 2 mm cuvette provided in the Nucleofector™ kit, the cuvette is inserted into the Nucleofector™ device, and the cells are electroporated. After electroporation, the cells are allowed to sit in the cuvette for 30-60 seconds at room temperature, and then they are transferred using a sterile transfer pipette to wells of a labeled 6-well plate (Falcon catalog number 351146, Corning, Durham, NC) containing 3 mL of cell culture medium. Transfected cells were plated in stationary 6-well plates in a humidified incubator at 36 °C and 6% CO 2Maintain them at 4 °C for 1–4 days, then culture them at 36 °C, 6% CO with shaking at 125 rpm until viability exceeds 90%. 2 into shake flask culture in cell culture medium at 7° C. After complete recovery of cells from transfection (as measured by viability in shake flask culture), the bulk culture is subjected to single cell sorting using FACS technology.
[0105] ZFN transfection for each target HCP can be performed once before single cell sorting. Alternatively, ZFN transfection for any particular target HCP can be performed twice, and complete cell recovery can be performed before the second ZFN transfection. More than one round of ZFN transfection can increase the number of cells that contain biallelic mutations in each target HCP, making screening more efficient.
[0106] Detection of ZFN-mediated targeted HCP sequence modifications in bulk cultures - General Procedure D Two to seven days after transfection, cells from partial to fully recovered ZFN bulk cultures are harvested for evaluation to assess the activity of the transfected ZFNs. The Surveyor® Mutation Detection Assay (MDA) (Transgenomic Inc., Omaha, NE) is used to detect the efficiency of the ZFN procedure in generating modifications at the target HCP site, following the manufacturer's protocol. Briefly, ZFN binding regions are PCR amplified using primers provided in the CompoZr® Custom Zinc Finger Nuclease Kit (Sigma, St. Louis, MO). The PCR products are then denatured and reannealed. The Cel-I endonuclease (Surveyor Nuclease S) provided in the MDA kit is used to detect DNA mismatch "bubbles" resulting from the annealing of PCR products consisting of native or wild-type sequences and those containing indels, because Cel-I recognizes these "bubbles" of mismatches and cleaves the DNA. After Cel-I digestion, the products are then separated on a 2% or 4% TBE agarose gel (Reliant Gel, Lonza, Basel, Switzerland). If there is no DNA mismatch "bubble", no DNA cleavage occurs and only one band is present, representing the PCR product. If any non-homologous end joining (NHEJ) occurs, representing ZFN activity, the cleavage products are observed on the gel in the form of two (or more) bands. Only ZFN bulk cultures that show a positive reaction in MDA are processed for single cell sorting.
[0107] Single-cell sorting by fluorescence-activated cell sorting – general procedure E The harvested bulk culture is sorted by fluorescence-activated cell sorting (FACS) technology. Protocols and methods for single cell cloning are well known in the art. For cloning, a cell sorter (MoFlo™ XDP, Beckman Coulter) is used to identify and sort single live cells by measuring laser diffraction in the forward and side scatter directions according to methods well known in the art (see, for example, Krebs, L., et al. (2015) “Statistical verification that one round of fluorescence-activated cell sorting (FACS) can effectively generate a clonally-derived cell line.” BioProcess J 13(4):6-19).
[0108] Cells are sorted into 96-well microtiter plates (Falcon, Cat. No. 35-3075) containing animal component-free selection medium (Ex-Cell CHO cloning medium, SAFC C6366) + 20% conditioned cell culture medium + phenol red (Sigma P0290). To prepare conditioned cell culture medium, parental cells are sorted into 1 x 10 6 Plate the cells at a density of 100 vc / mL in glutamine-free cell culture medium and incubate in shake flasks at 36 °C and 6% CO. 2 Incubate at 125 rpm for 20-24 hours. Centrifuge cultures to remove cells and filter conditioned medium through a sterile 0.22 μm filter. 7-10 days after single cell sorting, feed all plates with 50 μL of cell culture medium per well. 14-15 days after single cell sorting, analyze plates for clonal growth. Growth is determined by imaging sorted plates using a CloneSelect Imager (Molecular Devices, Sunnyvale, CA) or manually using a mirror and / or by observing the color change of the medium from red to orange / yellow.
[0109] Screening of clonally derived cell lines for ZFN-mediated targeted HCP sequence modifications - General Procedure F Clonal derived cell lines (CDCLs) are selected from the 96-well plates derived from the harvested ZFN bulk cultures as they become visible colonies and are transferred to deep 96-well plates (Greiner, Cat. No. 780271) containing cell culture medium. Clonal derived cell lines are consolidated into deep well plates containing 150 μL of cell culture medium. Cultures are maintained in cell culture medium under static conditions on a 3 day / 4 day feed / pass schedule until screening and characterization are completed.
[0110] The clonally derived cell lines (CDCL) are screened for indels using Surveyor® MDA. Genomic DNA is isolated from each cell line using Promega Wizard® SV 96 Genomic DNA Purification Kit (Cat. No. A2371, Promega, Madison, WI) according to the manufacturer's protocol. ZFN PCR reactions are performed using Phusion® High-Fidelity DNA Polymerase (New England BioLabs, Ipswich, MA) according to the manufacturer's protocol. MDA digestion products are separated on a 2% TBE agarose gel. Cell lines identified as positive in MDA are characterized by either General Procedure G or General Procedure H.
[0111] Characterization of indels in CDCLs using RT-PCR - General Procedure G: CDCLs are characterized by sequencing ZFN PCR products using targeted gene RT-PCR reactions. Total RNA is isolated from each potential KO cell line using RNeasy Micro Kit (Qiagen, Catalog No. 74004, Germantown, MD) according to the manufacturer's protocol. Reverse transcription reactions are performed using SuperScript™ III First-Strand Synthesis System for RT-PCR (Cat. No. 18080-051, Invitogen, Carlsbad, CA) according to the manufacturer's protocol, followed by PCR reactions using Phusion® High-Fidelity DNA Polymerase (New England BioLabs, Ipswich, MA) according to the manufacturer's protocol. RT-PCR products are separated on a 1% TAE agarose gel to identify cell lines with altered RT-PCR products. Cell lines selected for forward processing lack RT-PCR products and do not contain the targeted HCP protein by LCMS.
[0112] Characterization of indels in CDCLs using next generation sequencing (NGS) - General procedure H: MDA positive CDCLs are consolidated into 96-well deep well plates for further maintenance. Upon consolidation, cell lines that show "abnormal" PCR and / or MDA results are characterized using next generation sequencing (NGS) provided by GENEWIZ. Cell lines containing acceptable biallelic indels at the targeted HCP locus are assessed by LCMS, and cell lines that do not contain the targeted HCP protein are advanced.
[0113] Scaling and banking knockout cell lines - general procedure I: Based on the initial screening / characterization work, CDCLs requiring further evaluation are scaled from 96-well deep well plates (DWPs) into shake flasks to generate a research cell bank (RCB). From the DWPs, cells from the appropriate wells are transferred to appropriately labeled wells of a 6-well plate containing 3 mL of cell culture medium. The scaled CDCLs are transferred to stationary 6-well plates in a humidified incubator at 36 °C and 6% CO. 2 for 3-4 days, and then they were incubated at 36 °C, 6% CO with shaking at 125 rpm. 2 Transfer the cultures to a shake flask containing 15 mL of cell culture medium at 4°C. Passage the shake flask cultures at least once to establish a cell population suitable for banking. For each cell line, transfer 10–13 × 10 cells per vial in Freezing Menstrum (90:10 cell culture medium:DMSO). 6 Generate a 3-10 vial RCB in vc. Place the vials in a styrofoam rack "sandwich" at -80 °C for at least 24 h to allow the cells to freeze at a controlled rate. Once the vials are completely frozen, store them at -80 °C.
[0114] Example 3a - LPLA2 knockout CHO cell line CHO cells are prepared for gene disruption according to general procedure B. The cells are then subjected to single ZFN transfection and bulk culture harvest according to general procedure C. Sequence modifications in the bulk culture are detected using general procedure D. Bulk cultures that test positive in MDA are processed for single cell sorting according to general procedure E. The resulting clonally derived cell lines are then screened for the target HCP sequence modifications according to general procedure F. Indels are characterized according to general procedure G, and cell lines that do not contain detectable amounts of LPLA2 protein by LCMS are selected. RCBs are generated according to general procedure I to obtain LPLA2 knockout CHO cell lines.
[0115] Example 3b - LPLA2 / LPL knockout CHO cell line LPLA2 knockout CHO cells from Example 3a are prepared for gene disruption according to General Procedure B. The cells are then subjected to two rounds of ZFN transfection and bulk culture harvest according to General Procedure C. The sequence modifications of the bulk culture are detected using General Procedure D. Bulk cultures that test positive in MDA are processed for single cell sorting according to General Procedure E. The resulting clone-derived cell lines are then screened for the target HCP sequence modifications according to General Procedure F. Indels are characterized according to General Procedure H, and cell lines that do not contain detectable amounts of LPL protein by LCMS are selected. RCBs are generated according to General Procedure I to obtain LPLA2 / LPL knockout CHO cell lines.
[0116] Example 3c - LPLA2 / LPL / LAL knockout CHO cell line LPLA2 / LPL knockout CHO cells from Example 3b are prepared for gene disruption according to General Procedure B. The cells are then subjected to two rounds of ZFN transfection and bulk culture harvest according to General Procedure C. The sequence modifications of the bulk culture are detected using General Procedure D. Bulk cultures that test positive in MDA are processed for single cell sorting according to General Procedure E. The resulting clone-derived cell lines are then screened for the target HCP sequence modifications according to General Procedure F. Indels are characterized according to General Procedure H, and cell lines that do not contain detectable amounts of LAL protein by LCMS are selected. RCBs are generated according to General Procedure I to obtain LPLA2 / LPL / LAL knockout CHO cell lines.
[0117] Example 3d - LPLA2 / LPL / LAL / PPT1 knockout CHO cell line LPLA2 / LPL / LAL knockout CHO cells from Example 3c are prepared for gene disruption according to General Procedure B. The cells are then subjected to two rounds of ZFN transfection and bulk culture harvest according to General Procedure C. General Procedure D is used to detect sequence modifications in bulk culture. Bulk cultures that test positive in MDA are processed for single cell sorting according to General Procedure E. The resulting clone-derived cell lines are then screened for targeted HCP sequence modifications according to General Procedure F. Indels are characterized according to General Procedure H, but none of the cell lines contain biallelic mutations in the targeted PPT1 region. Cell lines containing monoallelic indels are evaluated by LCMS, and cell lines that do not contain detectable amounts of PPT1 protein by LCMS evaluation are advanced. RCB is generated according to General Procedure I to obtain LPLA2 / LPL / LAL / PPT1 knockout CHO cell lines.
[0118] Example 4 - Comparison of polysorbate stability in formulated mAbs expressed in LPLA2 / LPL / LAL / PPT1 knockout CHO cell lines and controls Fc fusion protein (Fc fusion protein 1) and antibody (antibody 2) are produced from a product-expressing CHO cell line in which LPLA2, LPL, LAL, and PPT1 are knocked out (referred to as "lipase / esterase KO cell line"), and as a control, a product-expressing CHO cell line in which LPLA2, LPL, LAL, or PPT1 are not knocked out. Fc fusion protein 1 is processed by protein A chromatography, low pH viral inactivation, anion exchange chromatography (AEX), cation exchange (CEX) chromatography, and tangential flow filtration (TFF) concentration, and then formulated with 0.02% PS80. Antibody 2 is processed by protein A chromatography, low pH viral inactivation, CEX chromatography, and TFF concentration, and then formulated with 0.02% PS80. Formulated samples of Fc-fusion protein 1 and antibody 2 are maintained at 25° C. for the duration of the study and used directly for LCMS analysis to monitor the percentage of intact PS80 remaining as the monooleate ester over time using general procedure A. The results are listed in Table 3 and show that PS80 in Fc-fusion protein 1 and antibody 2 produced using the KO cell line is more stable than the control sample. [Table 3]
[0119] Example 5 - Identification of PLD3 in monoclonal antibody preparations Samples containing 1 mg of antibody 3 processed by protein A capture, low pH viral inactivation, anion exchange (AEX) chromatography, and concentration to a concentration of 150 mg / mL by tangential flow filtration (TFF) are mixed with Tris-HCl buffer (1 M, pH 8, 5 μL) and water to a volume of 195 μL. Each solution is treated with 5 μL of Trispin and protein standard mixture (20 μL of 2.5 mg / mL r-bovine trypsin, 20 μL of protein standard mixture, and 60 μL of water) at 37 °C overnight. Each sample is mixed with 1,4-dithiothreitol (DTT, 50 mg / mL, 2 μL) and heated at 90 °C for 10 minutes, observing a white precipitate. The samples are then centrifuged at 13000 g for 2 minutes and the supernatant is transferred to an HPLC vial. Prior to LCMS analysis, samples are acidified with 5 μL of 10% formic acid in water, essentially as described in Example 2. In this experiment, PLD3 is identified in the Antibody 3 sample at 17±6 ng / mg (n=2) of Antibody 3.
[0120] Example 6 - Characterization of polysorbate hydrolysis activity of PLD4 and PLD7 Like PLD3, PLD4 and PLD7 are members of the phospholipase D family. The hydrolytic activity of PLD4 and PLD7 is assessed essentially as described in Example 1. Samples containing 0.02% PS80 are incubated with 0.25 and 2.5 units per milliliter (UN / mL) PLD4 and PLD7 at 35° C., and the percentage of intact PS80 remaining as monooleate ester is monitored over time by LCMS using general procedure A. After 35 hours of incubation under these conditions, PS80 is hydrolyzed by more than 30% and more than 80% in the presence of 2.5 UN / mL PLD4 and PLD7, respectively. These data are shown in FIG. 3, which qualitatively illustrates the ability of members of the PLD family to degrade PS80 over time.
[0121] Sequence Listing SEQ ID NO:1 - Chinese hamster palmitoyl protein thioesterase 1 (PPT1) MASPGSRWLLAVSLLPWCCAAWSLGHLNPPSLTPLVIWHGMGDSCCNPISMGAIKKMVEKEIPGIYVLSLEIGKNMMEDVENSFFLNVNSQVMMVCQILEKDPKLQQGYNAIGFSQGGQFLRAVAQRCPSPRMINLISVGGQHQGVFGLPRCP GESSHVCDFIRKMINAGAYSKVVQLRLVQAQYWHDPIKEDVYRNHSIFLADINQERCVNETYKKNLMALNKFVMVKFLNDSIVDPVDSEWFGFYRSGQAKETIPLQESTLYTEDRLGLKQMDKAGKLVFLAKEGDHLQLSKEWFNAYIIPFLK SEQ ID NO:2 - Chinese hamster lysosomal acid lipase (LAL) MQILGLVVCLFLSVLLSGRPTGSIPHVDPEANMNVTEMIRYWGYPSEEHMIQTEDGYILGVHRIPHGRKNHSHKGPKPVVYLQHGFLADSSNWVTNSDN SSLGFILADAGFDVWLGNSRGNTWSLKHRTLSISQDEFWAFSFDEMAKYDLPASIYYIVNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKKIKMFFAL APVVFLNFALSPVIKISKWPEVIIEDLFGHKQFFPQSAKLKWLSTHVCNRVVLKKLCTNVFFLICGFNEKNLNESRVNVYTSHSPAGTSVQNLRHWGQI AKHHMFQAFDWGSKAKNYFHYNQTCPPVYDLKDMLVPTALWSGDHDWLADPSDVNILLTQIPNLVYHKRLPDWEHLDFLWGLDAPWRMYNEIVNLLRKYQ SEQ ID NO:3 - Chinese hamster lipoprotein lipase isoform X2 (LPL) MESKALLLVALGVWLQSLTASQGXAAADGGRDFTDIESKFALRTPDDTAEDNCHLIPGIAESVSNCHFNHSSKTFVVIHGWTVTGMYESWVPKLVAALYKREPDSNVIVVDWLYRAQQ HYPVSAGYTKLVGNDVARFINWMEEEFNYPLDNVHLLGYSLGAHAAGVAGSLTNKKVNRITGLDPAGPNFEYAEAPSRLSPDDADFVDVLHTFTRGSPGRSIGIQKPVGHVDIYPNGG TFQPGCNIGEAIRVIAERGLGDVDQLVKCSHERSIHLFIDSLLNEENPSKAYRCNSKEAFEKGLCLLSCRKNRCNNVGYEINKVRAKRSSKMYLKTRSQMPYKVFHYQVKIHFSGTESD KQLNQAFEISLYGTVAESENIPFTLPEVSTNKTYSFLIYTEVDIGELLMMKLKWKSDSYFSWSDWWSSPGFVIEKIRVKAGETQKKVIFCAREKVSHLQKGKDSAVFVKCHDKSLKKSG SEQ ID NO:4 - Chinese hamster group XV phospholipase A2 isoform X1 (LPLA2) MDRHHLTCRATQLRSGLLVPLLLLMMLADLALSVQRHPPVVLVPGDLGNQLEAKLDKPKVVHYLCSKRTDSYFTLWLNLELLLPVIIDCWIDNIRLVYNRTSRATQFPDGVDVRVPGFGETFSLEFLDPSKRTVGSYFHTMVESLVGWGYTRGEDLRGAPYDWRRAPNENGPYFLALREMIEEMYQMYGGPVVLVAHSMGNMYTLY FLQRQPQAWKDKYIHAFISLGAPWGGVAKTLRVLASGDNNRIPVIGPLKIREQQRSAVSTSWLLPYNHTWSHDKVFVHTPTTNYTLRDYHQFFQDIRFEDGWF MRQDTEGLVEAMMPPGVELHCLYGTGVPTPDSFYYESFPDRDPKICFGDGDGTVNLESVLQCQAWQSRQEHKVSLQELPGSEHIEMLANATTLAYLKRVLFEP SEQ ID NO:5 - ZFN binding / cleavage nucleic acid sequence for LPLA2 TGGATCGCCATCACCTCACTTGTCGCGCGACCCAGCTCCGGAG SEQ ID NO:6 - ZFN binding / cleavage nucleic acid sequence for LPL AGCAAAGCCCTGCTCCTGGTGGCTCTGGGAGTGTGGCTCCAG SEQ ID NO:7 - ZFN binding / cleavage nucleic acid sequence for LAL TACTGGGGATACCCGAGTGAGGAGCATATGATCCAGAC SEQ ID NO:8 - ZFN binding / cleavage nucleic acid sequence for PPT1 CGCCTTCGCTGACACCGCTGGTGATCTGGCATGGGATGGGTA SEQ ID NO:9 - Chinese hamster phospholipase D3 (PLD3) MKPKLMYQELKVPVEEPAGELPVNEIEAWKAAEKKARWVLLVLILAVVGFGALMTQLFLWEYGDLHLFGPNQRPAPCYDPCEAVLVESIPEGLEFPNATTSNPSTSQAWLGLLAGAHSSLDI ASFYWTLTNNDTHTQEPSAQQGEEILQQLQALAPRGVKVRIAVSKPNGPLADLQSLLQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCLARDLTK IFEAYWFLGQAGSIPSTWPRPFDTRYNQETPMEICLNGTPALAYLASAPPPLCPSGRTPDLKALLSVVDSARSFIYIAVMNYLPTMEFSHPRRFWPAIDDGLRRAAYERGVKVRLLVSCWG HSEPSMRSFLLSLAALRDNHTHSDIQVKLFVVPADEAQARIPYARVNHNKYMVTERAVYIGTSNWSGSYFTETAGTSLLVTQNGHDGLRSQLEDVFLRDWNSLYSHNLDTAADSVGNACRLL SEQ ID NO:10 - ZFN binding / cleavage nucleic acid sequence for PLD3 GCCCCCTGCTATGACCCCTGCGAGTAAGTGGCAGGGGAG SEQ ID NO:11 - Chinese hamster fucosyltransferase 8 (FUT8) MRAWTGSWRWIMLILFAWGTLLFYIGGHLVRDNDHPDHSSRELSKILAKLERLKQQNEDLRRMAESLRIPEGPIDQGTATGRVRVLEEQLVKAKEQIENYKKQARNDLGKDHEILRRRIENGAKELWFFLQSELKKLKKLEGN ELQRHADEILLDLGHHERSIMTDLYYLSQTDGAGEWREKEAKDLTELVQRRITYLQNPKDCSKARKLVCNINKGCGYGCQLHHVVYCFMIAYGTQRTLILESQNWRYATGGWETVFRPVSETCTDRSGLSTGHWSGEVKDKNVQ VVELPIVDSLHPRPPYLPLAVPEDLADRLLRVHGDPAVWWVSQFVKYLIRPQPWLEREIEETTKKLGFKHPVIGVHVRRTDKVGTEAAFHPIEEYMVHVEEHFQLLERRMKVDKKRVYLATDDPSLLKEAKTKYSNYEFISDNS ISWSAGLHNRYTENSLRGVILDIHFLSQADFLVCTFSSQVCRVAYEIMQTLHPDASANFHSLDDIYYFGGQNAHNQIAVYPHQPRTKEEIPMEPGDIIGVAGNHWNGYSKGVNRKLGKTGLYPSYKVREKIETVKYPTYPEAEK SEQ ID NO:12 - Chinese hamster cathepsin D (CatD) MQTLGILLLAVGLLAASASAVIRIPLRKFTSIRRTMTEVGGSVEDLILKGPITKYSNQSPAETKGPVSELLKNYLDAQYYGEIGIGTPPQCFTVVFDTGSSN LWVPSIHCKLLDIACWIHHKYNSGKSSTFVKNGTSFDIHYGSGSLSGYLSQDTVSVPCKSEQPGGLKVEKQIFGEAIKQPGITFIAAKFDGILGMGYPSISV NNVVPVFDNLMQQKLVEKNIFSFFLNRDPTGQPGGELMLGGIDSKYYEGELSYLNVTRKAYWQVHMDQLDVANGLTLCKGGCEAIVDTGTSLLVGPVDEVKE LQKAIGAVPLIQGEYMIPCEKVSSLPSVTLKLGGKDYELSPSKYVLKVSQGGKTICLSGFMGMDIPPPSGPLWILGDVFIGTYYTVFDRDNNRVGFAKAATL SEQ ID NO:13 - ZFN binding / cleavage nucleic acid sequence for CatD CAGTGTCAGAGTTGCTCAAAAACTACCTGGATGTGAGTGAT SEQ ID NO:14 - Chinese hamster carboxypeptidase D (CpD) SEQ ID NO:15 - ZFN binding / cleavage nucleic acid sequence for CpD GTCAGTGGAGTCAAGAGAACTGTATGTGATGGAGATATC SEQ ID NO:16 - Chinese hamster phospholipase B-like 2 (PLBL2) MAAPMDRSPGGRAVRALRLALASLTEVLLNCPAGALPTQGPGRRRQNLDPPVSRVRSVLLDAASGQLRLVDGIHPYAVAWANLTNAIRETGWAYLDLGTNGSYNDSLQAYAAGVVEASVSEELIYMHWMNTMVNYCGPFEYEVG YCEKLKSFLEINLEWMQREMELSQDSPYWHQVRLTLLQLKGLEDSYEGRLTFPTGRFTIKPLGFLLLQIAGDLEDLEQALNKTSTKLSLGSGSCSAIIKLLPGARDLLVAHNTWNSYQNMLRIIKKYQLQFRQGPQEAYPLIAGNN LVFSSYPGTIFSGDDFYILGSGLVTLETTIGNKNPALWKYVQPQGCVLEWIRNIVANRLALDGATWADIFKQFNSGTYNNQWMIVDYKAFIPNGPSPGSRVLTILEQIPGMVVVADKTEDLYKTTYWASYNIPFFEIVFNASGLQD LVAQYGDWFSYTKNPRAQIFQRDQSLVEDMNSMVRLIRYNNFLHDPLSLCEACIPKPNAENAISARSDLNPANGSYPFQALYQRPHGGIDVKVTSFSLAKRMSMLAASGPTWDQLPPFQWSLSPFRSMLHMGQPDLWTFSPISVPWD SEQ ID NO:17 - ZFN binding / cleavage nucleic acid sequence for PLBL2 CGGTTCCTGCTCCGCTATCATCAAGTTGCTGCCAGGCGCACG SEQ ID NO:18-Chinese hamster peroxiredoxin-1 (PRDX1) MSSGNAKIGYPAPNFKATAVMPDGQFRDICLSEYRGKYVVFFFYPLDFTFVCPTEIIAFSDRAEEFKKLNCQVIGASVDSHFCHLAWINTPKKQGGLGPMNIPLVSDPKRTIAQDYGVLKADEGISFRGLFIIDDKGILRQITINDLPVGRSVDEILRLVQAFQFTDKHGEVCPAGWKPGSDTIKPDVQKSKEYFSKQK SEQ ID NO:19 - ZFN binding / cleavage nucleic acid sequence for PRDX1 CCTGCCCCCAACTTCAAAGCCACAGCTGTTATGCCAGATGGAC
Claims
1. A recombinantly engineered mammalian cell having reduced expression and / or reduced activity of at least one endogenous host cell protein (HCP) palmitoyl protein thioesterase, and at least one other endogenous HCP selected from the group consisting of lipoprotein lipase, lysosomal acid lipase, phospholipase D, and phospholipase A2.
2. 2. The cell of claim 1, comprising a disrupted or inactivated gene encoding a HCP palmitoyl protein thioesterase and at least one disrupted or inactivated gene encoding a HCP selected from the group consisting of lysosomal acid lipase protein, lipoprotein lipase protein, phospholipase D, and phospholipase A2 protein.
3. 3. The cell of claim 1 or 2, wherein the palmitoyl protein thioesterase is at least one inactivated gene encoding a HCP selected from the group consisting of PPT1, LAL, LPL, PLD3 and LPLA2.
4. The cells are capable of detecting the lysosomal acid lipase (LAL) protein, the lipoprotein lipase (LPL) protein, the phospholipase A2 (LPLA 2 4. The cell according to claim 1, comprising a modification in the coding sequence of a polynucleotide encoding said palmitoyl protein thioesterase 1 (PPT1) protein.
5. The cells are capable of detecting the lysosomal acid lipase (LAL) protein, the lipoprotein lipase (LPL) protein, the phospholipase A2 (LPLA 2 ) protein, and the palmitoyl protein thioesterase 1 (PPT1) protein, wherein the modification increases the expression levels of the LAL protein, the LPL protein, the LPLA protein, and the LAL protein in cells having the modification compared to cells not having any of the modifications. 2 The cell according to any one of claims 1 to 3, wherein the expression level of the PPT1 protein is reduced.
6. The cell of claim 4 or 5, wherein the cell does not express detectable levels of the LAL protein, the LPL protein, the LPLA2 protein, and the PPT1 protein.
7. The cell according to any one of claims 4 to 6, wherein the modification comprises a nucleotide insertion or deletion within exon 1 or 2 of the coding sequence of the polynucleotide encoding the specific protein.
8. The modification is a) a nucleotide insertion or deletion within exon 1 of the coding sequence of the polynucleotide encoding the LPL, LPLA2, and PPT1 proteins, and The cell according to any one of claims 4 to 7, comprising a nucleotide insertion or deletion in exon 2 of the coding sequence of the polynucleotide encoding the LAL protein.
9. The cell described in claim 8, wherein the PPT1 protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
1.
10. The cell of claim 9, wherein the modification comprises a nucleotide insertion or deletion within SEQ ID NO:
8.
11. The cell of claim 8 , wherein the LAL protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
2.
12. The cell of claim 11 , wherein the modification comprises a nucleotide insertion or deletion within SEQ ID NO:
7.
13. The cell of claim 8 , wherein the LPL protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
3.
14. The cell of claim 13 , wherein the modification comprises a nucleotide insertion or deletion within SEQ ID NO:
6.
15. The cell of claim 8 , wherein the LPLA2 protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
4.
16. The cell of claim 15, wherein the modification comprises a nucleotide insertion or deletion within SEQ ID NO:
5.
17. 17. The cell of any one of claims 1 to 16, wherein the modification comprises a nucleotide insertion or deletion within exon 2, exon 3, or exon 4 of the coding sequence of the polynucleotide encoding a protein from the list consisting of PPT1, LAL, LPL, and LPLA2.
18. The cell of any one of claims 1 to 17, further comprising a polynucleotide encoding one or more biological products.
19. 20. The cell of claim 18, wherein the bioproduct is selected from the group consisting of an antibody, an antibody heavy chain, an antibody light chain, an antigen-binding fragment, an antigen-binding protein, a protein-protein fusion, and an Fc fusion protein.
20. 20. The cell of any one of claims 4 to 19, wherein the cell produces a Protein A binding fraction that has a polysorbate degrading activity that is substantially reduced compared to the polysorbate degrading activity of a cell not having any of said modifications.
21. 21. The cell of claim 20, wherein the reduction in degradation of intact polysorbate is 30% or more.
22. 21. The cell of claim 20, wherein the reduction in degradation of intact polysorbate is 30% or more.
23. The cell according to any one of claims 1 to 22, wherein the cell is a CHO cell.
24. 24. The cell of claim 23, wherein the cell is a CHO-K1 cell, a CHOK1SV cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHO-S, a CHO GS knockout cell (glutamine synthetase), a CHOK1SV FUT8 knockout cell, a CHOZN, or a CHO-derived cell.
25. (a) obtaining a sample comprising a biological product and a plurality of host cell proteins from a host cell that has been modified to produce a reduced level of PPT1 compared to an unmodified cell; and (b) subjecting said sample to at least one purification step to remove at least one host cell protein.
26. 26. The method of claim 25, wherein the plurality of host cell proteins (a) does not include a detectable amount of PPT1 protein, and (b) does not include a detectable amount of at least one other lipase or esterase.
27. The host cell comprises a) a modification in the coding sequence of a polynucleotide encoding the PPT1 protein, and b) Lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase A2 (LPLA2) 、 27. The method of claim 25 or 26, comprising a modification in the coding sequence of a polynucleotide encoding a fatty acid hydrolase selected from the group consisting of phospholipase D3 (PLD3), or a combination thereof.
28. 28. The method of any one of claims 25 to 27, wherein the purification step is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC).
29. 1. A method for reducing polysorbate degradation in a protein formulation, comprising: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying the host cell to produce lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 reducing or eliminating the expression of (c) transfecting the cells with a polynucleotide encoding a biological product; (d) extracting a protein fraction containing the protein of interest from the host cells; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) collecting said protein of interest from said medium; (g) mixing the bioproduct with a fatty acid ester; (h) optionally adding a buffer, then (i) optionally, adding one or more pharma- ceutically acceptable carriers, diluents, or excipients.
30. 1. A method for reducing aggregation or particle formation in a protein formulation, comprising: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying the host cell to produce lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 reducing or eliminating the expression of (c) transfecting the cells with a polynucleotide encoding a biological product of interest; (d) extracting a protein fraction containing the protein of interest from the host cells; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) collecting said protein of interest from said medium; (g) mixing said protein of interest with a fatty acid ester; (h) optionally adding a buffer, then (i) optionally, adding one or more pharma- ceutically acceptable carriers, diluents, or excipients.
31. 1. A method for producing a stable formulated biological product, comprising: (a) modifying a host cell to reduce or eliminate expression of palmitoyl protein thioesterase 1 (PPT1) protein; (b) modifying the host cell to produce lysosomal acid lipase (LAL), lipoprotein lipase (LPL), phospholipase D3 (PLD3), and / or phospholipase A2 (LPLA 2 ) reducing or eliminating expression of (c) transfecting the cell with a polynucleotide encoding a biological product; (d) extracting a protein fraction comprising the bioproduct from the host cell; (e) contacting the protein fraction with a chromatography medium, which is Protein A affinity (PA) chromatography or another affinity chromatography method, cation exchange (CEX) chromatography, anion exchange (AEX) chromatography, or hydrophobic interaction chromatography (HIC); (f) harvesting the biological product from the medium; (g) mixing the bioproduct with a fatty acid ester; (h) optionally adding a buffer; and then (i) optionally adding one or more pharma- ceutically acceptable carriers, diluents, or excipients.
32. 32. The method of any one of claims 29 to 31, wherein the step of modifying the host cell to reduce or eliminate the expression of PPT1 comprises inserting or deleting at least one nucleotide within exon 2, exon 3, or exon 4 of the polynucleotide encoding the PPT1 protein.
33. The method of any one of claims 29 to 32, wherein the polynucleotide encoding the PPT1 protein comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:
1.
34. The method of any one of claims 29 to 33, wherein the expression and / or activity of any of the phospholipases produced by the cell is reduced.
35. 35. The method of claim 34, wherein the decreased expression and / or activity is determined by assaying for lipolytic activity.
36. A pharmaceutical composition comprising a polysorbate and a biological product produced by a mammalian cell according to any one of claims 1 to 24.
37. A pharmaceutical composition comprising a polysorbate and a biological product produced by the method of any one of claims 29 to 35.
38. The biological product is selected from the group consisting of tanezumab, lebrikizumab, mirikizumab, solanezumab, donanemab, zagotenemab, ramucirumab, galcanezumab, ixekizumab, dulaglutide, necitumumab, olaratumab, cetuximab, angiopoietin 2 mAb, insulin-Fc fusion protein, CD200R agonist antibody, epiregulin / TGFα mAb, ANGPTL 3 / 8 antibody, BTLA antibody agonist, CXCR1 / 2 ligand antibody, GDF15 agonist, IL-33 antibody, PACAP38 antibody, PD-1 agonist antibody, N3pG Abeta 38. The pharmaceutical composition of claim 37, wherein the antibody is selected from the group consisting of pGlu-Abeta, also referred to as mAb, TNFα / IL-23 bispecific antibody, anti-α-synuclein antibody, CD226 agonist antibody, MCT1 antibody, SARS-CoV-2 neutralizing antibody, FcgRIIB antibody, IL-34 antibody, CD19 antibody, TREM2 antibody, and relaxin analog, and polysorbate, said bioproduct produced by a recombinant mammalian cell of the invention.
39. A biological product produced by the method of any one of claims 29 to 35.
Citation Information
Patent Citations
Host cell protein modification
WO2018039499A1
